{"schema_version":"secwatch.filing_event.v1","accession":"0001503274-25-000074","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2025-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.149257+00:00","generated_at":"2026-05-18T05:39:26.768541+00:00","sec_items":["2.05","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Quanterix terminates Akoya executives post-acquisition; expects $2.8M annual savings, $3.3M severance cost","bullets":["Terminating certain Akoya executives under its Executive Severance Plan as part of integration.","Expects annualized cash savings of ~$2.8M from reduced costs and streamlined operations.","Anticipates ~$3.3M in severance expenses, all cash expenditures, in 2025.","Terminations part of plan to realize synergies from recently closed Akoya acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0001503274-25-000074","json":"https://secwatch.observer/filing/0001503274-25-000074.json","markdown":"https://secwatch.observer/filing/0001503274-25-000074.md","text":"https://secwatch.observer/filing/0001503274-25-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000150327425000074/0001503274-25-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000150327425000074/qtrx-20250714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:39:26.768541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14e658aaa2348b5bb7edef5b98c46e6829f74498","claim":"Quanterix Corp announced a restructuring with charges of approximately $3.3 million affecting Akoya Biosciences, Inc. (newly acquired subsidiary) (certain executives of the Company's newly acquired subsidiary, Akoya Biosciences, Inc.).","evidence_excerpt":"costs and streamlined operations and are expected to result in annualized cash savings of approximately $2.8 million. The Company expects to incur expenses of approximately $3.3 million, substantially all of which will be cash expenditures incurred in 2025 for severance required under Akoya’s Executive Severance Plan. The Company’s estimates are based on a","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503274/000150327425000074/0001503274-25-000074-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.3 million"},{"label":"Affected area","value":"Akoya Biosciences, Inc. (newly acquired subsidiary)"},{"label":"Headcount","value":"certain executives of the Company's newly acquired subsidiary, Akoya Biosciences, Inc."}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}